Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002453419 | SCV002616648 | pathogenic | Familial thoracic aortic aneurysm and aortic dissection | 2016-10-24 | criteria provided, single submitter | clinical testing | The p.G1188R pathogenic mutation (also known as c.3562G>A), located in coding exon 48 of the COL3A1 gene, results from a G to A substitution at nucleotide position 3562. The glycine at codon 1188 is replaced by arginine, an amino acid with dissimilar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Schwarze U et al. Am J Hum Genet. 1997;61(6):1276-1286; Pepin MG et al. Genet Med. 2014;16(12):881-8). The p.G1188R mutation (reported with the legacy nomenclature p.G1021R) has been detected in two unrelated individuals with Ehlers-Danlos syndrome type IV (EDS IV), and cultured skin fibroblasts from both patients have been shown to produce abnormal type III procollagen (Pope FM et al. Br. J. Dermatol. 1996;135:163-81; Pepin M et al. N. Engl. J. Med. 2000;342:673-80). In addition, two other alterations associated with EDS IV, p.G1188V and p.G1188E, have been described in the same codon (Narcisi P et al. Am. J. Med. Genet. 1993;46:278-83; Drera B et al. J. Dermatol. Sci. 2011;64:237-40). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Collagen Diagnostic Laboratory, |
RCV000087439 | SCV000120325 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |